The two-drug regimen dolutegravir plus lamivudine demonstrated durable efficacy for up to
3 years in phase III studies and a high barrier to resistance in treatment-naive and …

Objectives Dolutegravir (DTG) is widely recommended within three‐drug regimens.
However, similar efficacy and tolerability have also been achieved with DTG within two‐drug …

Background: The SWORD trials showed that in participants who achieved virologic
suppression taking 3-drug or 4-drug regimens, switching to the 2-drug regimen dolutegravir …

Objectives The aim of this study was to assess the efficacy of dolutegravir plus lamivudine
(DTG+ 3TC) in a large set of virologically suppressed HIV-1 infected individuals with or …

Objectives The aim of the present study was to compare the efficacy and durability of
treatment switch to two‐drug (2DR) vs. three‐drug (3DR) integrase inhibitor (InSTI)‐based …

Objectives In the HIV-1-positive population, a paradigm shift from three-drug regimens
(3DRs) to dolutegravir-based two-drug regimens (2DRs) both as initial and switch treatment …

This was a retrospective study on the efficacy and drug resistance mutations selected at
virological failure (VF) in prospectively-followed HIV-infected patients switched to …

Introduction Second-generation integrase strand transfer inhibitors such as bictegravir (BIC)
and dolutegravir (DTG) are the standard of care for starting therapy in people living with HIV …

Background: The high effectiveness and safety of the two-drug (2DRs) strategy using
dolutegravir (DTG) plus lamivudine (3TC) have led to international guidelines …

PNP is an employee of the Université catholique de Louvain. AC was and PW and P.-FL are
employees of the Cliniques universitaires Saint-Luc. PMT was unpaid. FVB is Research …